Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually not an option. Median overall survival without treatment is just a few months but with systemic chemotherapy this can be improved.

This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line.

Key clinical takeaways:

• mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
• Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
• Choice of 2nd line treatment should be guided by prior regimen and patient fitness
• Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0

Or watch on YouTube: https://youtu.be/8YxRnjOYUv4

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/giconnect

X: https://x.com/giconnectInfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Ipsen USA.

This podcast is developed by cor2ed.com

Published May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague, President of Lung Cancer Europe (LuCE) and founder of ALK Positive UK.

As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.

Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey.

What does the patient pathway look like from both perspectives? What are the needs of Medical Oncologists and patients when navigating the treatment journey? What do patients need from their oncologists? What do oncologists think their patients need from them? Are these needs matched by the support currently available?

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com

Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC

This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.

In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC.

The conversation unfolds to cover;

• How to distinguish HER2 alterations from other alterations on biomarker reports

• The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC

• The potential CNS activity of these treatments in patients with HER2-mutated NSCLC

• How the treatment pathway may look in the near future

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/

Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y

Follow LUNG CONNECT on social media:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Bayer.

This podcast is developed by cor2ed.com

Published on May 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.